Status:
COMPLETED
Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
Lead Sponsor:
Thomas Jefferson University
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Intrahepatic Cholangiocarcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This phase II trial tests whether contrast-enhanced ultrasound can predict the response of bile duct cancer to targeted radiotherapy (radioembolization treatment). Contrast-enhanced ultrasound uses ga...
Detailed Description
PRIMARY OBJECTIVE: I. To determine the ability of quantitative volumetric contrast-enhanced ultrasound (CEUS) to predict non-hepatocellular carcinoma (HCC) tumor response to transarterial radioemboli...
Eligibility Criteria
Inclusion
- Be scheduled for sub-lobar radioembolization therapy of a previously untreated intrahepatic cholangiocarcinoma greater than 1 cm but small enough to be fully visualized in the ultrasound three-dimensional (3D) volume (approximately 6 cm maximum diameter, but depth dependent)
- Be at least 18 years of age
- Be medically stable
- If a female of child-bearing age, have a negative pregnancy test prior to each ultrasound exam
- Have signed Informed Consent to participate in the study
Exclusion
- Females who are pregnant or nursing
- Patients with recent cerebral hemorrhage
- Patients with known sensitivities to albumin, blood, or blood products
- Patients with known hypersensitivity to perflutren
- Patients with known congenital heart defects
- Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli
- Patients with bilirubin levels \> 2 mg/dL
Key Trial Info
Start Date :
December 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2025
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT05328167
Start Date
December 14 2021
End Date
August 31 2025
Last Update
October 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107